Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Wynn Resorts Ltd WYNN

Wynn Resorts, Limited is a designer, developer, and operator of integrated resorts featuring luxury hotel rooms, high-end retail space, dining and entertainment options and gaming. Its segments include Wynn Palace, Wynn Macau, Las Vegas Operations, Encore Boston Harbor and Wynn Interactive. Its Wynn Palace is a luxury resort on the Cotai Strip in Macau, with approximately 1,706 guest rooms, suites and villas, 14 food and beverage outlets and meeting and convention space. Its Wynn Macau is a luxury resort located in the Macau Special Administrative Region of the People's Republic of China with approximately 1,010 guest rooms and suites, approximately 4 food and beverage outlets, convention space, and a performance lake, a rotunda shows and recreation and leisure facilities. The Company's Encore Boston Harbor is a luxury resort with approximately 671 hotel rooms, an spa, specialty shopping, 16 food and beverage outlets, nightclub and meeting spaces, waterfront park and floral displays.


NDAQ:WYNN - Post by User

Post by Maemae4on Jun 03, 2022 5:31am
78 Views
Post# 34728785

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance



FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.


 
<< Previous
Bullboard Posts
Next >>